This study, called EncompaSSc, is testing a new treatment called MTX-474 for people with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a type of antibody that targets EphrinB2. The study aims to see if MTX-474 is safe and effective in improving skin hardening, a common symptom of dcSSc. You might be able to join if you have dcSSc, are within two years of your first non-Raynaud's symptom, and have a Modified Rodnan Skin Score (mRSS) greater than 7. Participants will receive either MTX-474 or a placebo (an inactive substance) through an IV infusion every four weeks. The main goal is to see how much your mRSS changes over 24 weeks. The current recruitment status is unclear.

Study design

This is a Phase 2, randomized, double-blind, placebo-controlled study involving about 85 participants. You would be randomly assigned to receive either MTX-474 or a placebo.

What's involved

You would receive IV infusions every 4 weeks for 20 weeks, with visits for assessments like skin scores, breathing tests (spirometry), and blood draws. You would also have a safety follow-up visit 8 weeks after your last infusion.

Compensation

Not stated in the trial record.

Follow-up

You would have a safety follow-up visit at Week 28, which is 8 weeks after the final infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.